结核杆菌耐利福定与细菌RNA聚合酶变异关系的研究  

STUDIES ON THE RELATIONSHIP BETWEEN THE ALTERATION OF RNA POLYMERASE IN MYCO-BACTERIUM TUBERCULOSIS H_(37)Rv AND THE RESISTANCE INDUCED BY RIFANDIN

作　　者：李显志[1] 张欣凤[1] 蒋天蓉 王浴生[1] 

机构地区：[1]华西医科大学基础医学院药理室

出　　处：《中国抗生素杂志》1989年第5期311-314,共4页Chinese Journal of Antibiotics

基　　金：国家自然科学基金;华西医科大学青年科学基金资助项目

摘　　要：选用结核杆菌H37Rv,于体外诱导筛选获得耐利福定（1250μg/ml）菌株,检测了利福定抗结核杆菌活性及其与6种常用抗结核药物的交叉耐药性;以3H-尿苷进行掺入实验,发现利福定明显抑制3H-尿苷掺入敏感菌,而对掺入耐药菌则无抑制;提取及分析结核杆菌RNA聚合酶,发现敏感菌酶活性受利福定明显抑制,耐药菌酶活性则未见抑制。结果提示:结核杆菌耐利福定与耐药菌RNA聚合酶改变有关。Rifandin(RFD, R76-1) is a semisynthetic antituberculous agent made in China. The RFD-resistant strain was induced from Mycobacterium tuberculosis H37Rv propagated on Lowenstein-Jensen medium with concentration gradients of RFD. The anti-bacterial activity of RFD on M.tuberculosis and the cross-resistance of RFD with other six antituberculous drugs were tested. The incorporation of ~3H-Uridi-ne into H37Rv strain was significantly inhibited by RFD and RFD failed to inhibit the incorporation in the resistant strain.The RNA polymerase activity of H37Rv strain was strongly inhibited by RFD, but not that of the resistant strain. Our results suggested that one of the resistant mechanisms of M. tuberculosis to RFD is re lated to an alteration of RNA polymerase in its resistant strain.

关 键 词：利福定 结核杆菌 RNA聚合酶 

分 类 号：R978.3[医药卫生—药品]